Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Pwil, it would be very disappointing if months away. Id like to think we will get an update on trial programme soon. If the aspiration is to report 3 results at the American Society of Haematology conference in early December and assuming they use November to prepare the presentation - then perhaps the third trial starts early October (and trial one and two early August and September respectively). Im hoping trials RNS July therefore if not before - although will that move the sp? a favourable milestone payment RNS surely would. Good luck with your top up
. thank you Hul.
maybe I shouldn’t be invested because I’ve got to keep reading over.
‘’these results highlight a need to tailor therapy to limit cytokine effects on AML blasts to improve outcomes with AML-directed CAR T cell therapy’s’’
What the fk are you talking about SS? What is India calling exactly? We can all see the stock has a low mcap compared to peers - we dont need him bleating about HEMO and Vlad everyday. Are you now suggesting he has some really deep insight - shall we follow the moan?
Is funding not secured to embark on Ph 1 trials? if you dont believe that why remain invested - just to fkn moan day in day out? and what is this truth that is being supressed
India you say everyone is just 'speculating in trying to ramp or deramp the price' and then say it is dead as a dodo - you never seem to notice the hypocrisy in most of what you post. You never got back about your 3 big cheese pharma mates who are invested here? And would you mind pinpointing exactly what things Vlad promised?
This is dead as a dodo until we get some update on all the things vlad promised us as always !!!
Not quite made up Gold...
https://www.proactiveinvestors.co.uk/companies/news/1044876/hemogenyx-pharmaceuticals-important-raise-and-car-t-potential-makes-it-one-to-watch-1044876.html?viewSource=TwitterUK
''Hemogenyx will use the newly raised funds to take HEMO-CAR-T into the clinic to treat AML later this year.
The open-label study will test for any potential side effects from treating people with blood-borne diseases and assess how the therapy interacts with the body.
A secondary goal or 'endpoint' will be whether any of the critically ill AML patients chosen for the trial respond to the CAR-T infusion.
Under the strict guidelines laid down by the US Food & Drug Administration, patients will be dosed individually one month apart, recognising people are being administered with a potentially toxic cells.
Hemogenyx hopes to have the results from “two, or even three patients” in time for the American Society of Hematology conference in early December.
Success at this stage would be a 30% response rate, says Dr Vladislav Sandler, chief executive and co-founder of Hemogenyx.
Investigational work will be carried out by a team from the University of Pennsylvania, led by Professor Nolle Frey, who has headed a number of important CAR-T clinical trials.
The entre was provided by Professor Carl June, the ‘father’ of CAR-T, and his colleague, Dr Saar Gill, who was involved in the preclinical research on HEMO-CAR-T.
On the university’s involvement, Sandler said: “This isn’t a situation where we’ve paid [UPenn] to carry out the work. They don’t work like that. All along it been data driven.”
While no guarantee of success, it provides validation for the science behind the efforts of Hemogenyx.
So expensive is the process of creating individual CAR-T treatments, that cash raised in February may be enough to dose three patients.
Hemogenyx will look to further non-dilutive funding to assess a cohort of around 18 AML sufferers, which will take it to the phase II stage of the clinical evaluation.
This is key, as it is the point that big pharma has weighed into the sector with the deals mentioned above''
I think you are right HT. some of the herd move on - things take time in Pharma. But I cant see any reason why they wont return in significant numbers over the coming months. While dates in that article cant be considered a given it does shed an interesting perspective on what we might expect before year end.
Great post? are you fkn joking. Same old regurgitated moaning drivel from India that he’s been posting for months. What happened to his 3 big cheese Pharma mates who told him this was the best thing since sliced bread. He attacks Vlad (defames in fact) but doesn’t like his own view countered. Lazy
Isn’t the drift down just some of the herd moving on / getting bored and looking for a bit of action elsewhere. It is disappointing with the additional shares in play and some delay, BUT that raise allows HEMO to progress CAR T to trials!! I’m looking forward to the journey - I still feel holders will see value increase significantly in the coming months. Why shouldn’t HEMO CAR T match the value of its peers…
You mention ''the risk to the company'' JHFH - do you mean risk in securing finance? Im confident a solution will be found which will help stimulate a market cap close to the peer group, just perhaps not quite within the timeframe many of us hoped